echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > AstraZeneca vs. Pfizer acquisition: seeking partners for ad drugs

    AstraZeneca vs. Pfizer acquisition: seeking partners for ad drugs

    • Last Update: 2014-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: DXY 2014-05-09 AstraZeneca is negotiating with other companies to seek partners for its experimental drugs for Alzheimer's disease in order to resist Pfizer's US $106 billion offer Briggs Morrison, global director of drug research and development, said AstraZeneca has talked with their company about the development of so-called bace inhibitors AstraZeneca is ready to share more of its experience with Alzheimer's as the drug nears the final stage of phase III development On Wednesday, he told reporters that sharing phase III cost and final profit share may be the easiest way, but AstraZeneca can also license azd3293 varieties and obtain royalties paid by other companies in the final sale AstraZeneca believes that bace inhibitors can achieve $5 billion in annual sales, but it only gives a 9% success rate on the adjusted risk benchmark "We've talked to many very experienced colleagues who have done in-depth research on Alzheimer's disease." Morrison said: 'although no agreement has been reached, we are still negotiating On Tuesday, AstraZeneca touted its strong long-term potential as an independent company to fight Pfizer's takeover plans In fact, most of AstraZeneca's drugs under study are focused on cancer, diabetes, respiratory and cardiovascular fields Neurological projects including Alzheimer's are not the core areas of the group Bace inhibitors inhibit β - amyloid production by blocking β - secretase The protein forms plaques in the brain and is believed to be the main cause of Alzheimer's disease This is regarded as the most promising method to fight memory loss After the failure of Pfizer and Eli Lilly led injection targeting β - amyloid plaque drug test, the treatment has been in the center Merck is now a leader in the field of BACE inhibitors The earliest phase III data from its U.S branch confirms this, which is likely to be fully presented in 2017 Dementia, the most common form of Alzheimer's disease, has affected 4400 people worldwide and will grow to 135 million by 2050, according to the international non-profit organization for Alzheimer's disease Alzheimer's disease is different from heart disease and cancer There has been no significant progress since FDA approved the first drug in this field in 1993 At present, the drugs for Alzheimer's disease, including Pfizer's donepezil, can only slightly and temporarily improve memory and daily behavior, but not slow down the course of disease Source address: http:// Feedtype = rss & feedname = HealthNews
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.